Singapore Exchange (SGX) is pleased to welcome the listing of QT Vascular Ltd on Catalist under the stock code “5I0”.
QT Vascular develops and distributes advanced medical devices for the treatment of complex vascular diseases. The company plans to expand its reach and expertise into the rest of Asia with Singapore as its regional hub.
“We are excited that our IPO has attracted strong interest from investors who identify with our vision and expansion plans in Singapore and worldwide. With the proceeds from the IPO, we intend to focus on the commercial expansion of our existing products and invest in our pipeline of new products and product enhancements” said Dr Eitan Konstantino, CEO of QT Vascular.
Lawrence Wong, Head of Listings at SGX, said, “We welcome QT Vascular to Catalist, the latest addition to our healthcare sector. The listing provides the company with a platform for accessing funds and growing its business. At the same time, market participants will have wider choices when investing in this growth cluster on SGX.”
The listing of QT Vascular brings the total number SGX-listed healthcare companies to 27 with a market value of $27 billion. With QT Vascular listed, the Catalist board will have 142 companies with total market capitalisation of $10 billion.
